Saxenda at two weeks: what early GLP-1 results actually mean

What did @valezubiaurr actually say?

Honestly, not much that we can fact-check with any confidence. The transcript available for this video is a garbled, machine-translated mess that bears almost no resemblance to coherent medical claims. The creator is two weeks into a Saxenda (liraglutide) treatment journey and sharing their early experience, but the substance of what they actually said is lost in translation noise.

What we can infer from context: this is a personal experience video from Chile, hashtagged as a weight loss journey, filmed at the two-week mark of liraglutide therapy. That timeline matters. Two weeks on Saxenda is still the dose-escalation phase for most patients. The standard protocol starts at 0.6 mg daily and steps up weekly, meaning most people at the two-week mark are not yet at the therapeutic dose of 3.0 mg. Whatever results they're reporting, early is genuinely early here.

The video has 142,500 views, which means whatever @valezubiaurr experienced is shaping expectations for a significant audience. That's worth examining carefully.

Does the science back up early Saxenda experiences?

Two weeks is too soon to judge Saxenda's weight loss effects, but it's not too soon to feel side effects. The clinical data on liraglutide is actually pretty solid, but the first two weeks rarely tell the real story.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found that patients on liraglutide 3.0 mg lost an average of 8.4 kg over 56 weeks compared to 2.8 kg on placebo. That's meaningful. But the weight loss curve is not linear, and it doesn't really accelerate until patients reach the full therapeutic dose, which takes roughly five weeks of titration under the standard schedule.

Nausea, fatigue, and appetite suppression in the first two weeks are well-documented and common. In the SCALE trial, nausea affected roughly 40% of participants, predominantly in the early titration phase. So if @valezubiaurr is reporting feeling rough at two weeks, that tracks with the pharmacology. Liraglutide activates GLP-1 receptors in the gut and brainstem, slowing gastric emptying, which is effective for weight loss but genuinely uncomfortable early on.

What did they get wrong, or right?

We cannot fairly assess accuracy without a legible transcript. That caveat matters. What we can say is that personal experience videos at the two-week mark carry a specific risk: they prime viewers to expect either dramatic early results or early dropout due to side effects, neither of which reflects average outcomes at full therapeutic dose.

If the creator is accurately reporting early side effects like nausea or reduced appetite, that's consistent with the literature and reasonably honest. GLP-1 agonist side effects are real and front-loaded in treatment. Telling an audience that the first two weeks are hard is actually useful, not alarmist.

Where personal experience videos on Saxenda routinely go wrong is in generalizing individual timelines. Weight loss onset, side effect severity, and dose tolerance vary significantly by individual. Davies et al. (2015, International Journal of Obesity) noted substantial inter-individual variability in liraglutide response, driven partly by baseline BMI, dietary patterns, and GLP-1 receptor sensitivity. One person's two-week experience is a data point of one.

What should you actually know about Saxenda at two weeks?

The two-week mark on Saxenda is almost entirely about tolerability, not results. If you're watching this video hoping to see dramatic weight loss, you're looking at the wrong timepoint.

Here's what the evidence says about early liraglutide treatment:

• Most patients are still titrating the dose at two weeks and have not reached the 3.0 mg therapeutic target.
• Nausea, vomiting, and constipation peak during titration and typically improve once the dose stabilizes (Astrup et al., 2012, International Journal of Obesity).
• Appetite suppression is real early on, even at sub-therapeutic doses, because GLP-1 receptors in the hypothalamus respond to liraglutide at lower concentrations.
• Measurable weight loss at two weeks is modest in most patients, typically 1-3 kg depending on baseline caloric intake changes.
• Saxenda requires a prescription and medical supervision in Chile, where it is approved by the Instituto de Salud Pública. It is not an over-the-counter product.

Personal experience content has value. But 142,000 viewers deserve context that individual experiences at two weeks are not predictive of outcomes at 16 or 56 weeks.